Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche span> par promoteur : Novartis Pharma AG
Femme et Homme Max 99 ans
Novartis Pharma AG
MAJ Il y a 5 ans
A multi-center, randomized, double-blind, placebo- controlled, two-period cross-over study to assess the effect of 50µg inhaled NVA237 on exercise endurance in patients with moderate to severe COPD
To determine the effect of 50 µg NVA237 compared with matching placebo inhaled once daily on exercise tolerance as measured by exercise endurance time during a sub-maximal constant-load cycle ergometr...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma AG
MAJ Il y a 5 ans
A multicenter, double-blind, randomized, active controlled, parallel group study to compare the effect of 12 weeks treatment with LAF237 50 mg BID to 50 mg OD in patients with type 2 diabetes with HbA1c 9-11%. 52 week extension to a multicenter, double-blind, randomized, active controlled, parallel group study to compare the effect of 12 weeks treatment with LAF237 50 mg BID to 50 mg OD in patients with type 2 diabetes with HbA1c 9-11%
To demonstrate the efficacy of LAF237 in patients with type 2 diabetes with HbA1c 9- 11% by testing the hypothesis that the HbA1c reduction with LAF237 50 mg BID is superior to that with LAF 237 50 mg...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma AG
MAJ Il y a 5 ans
A double-blind, randomized, placebo-controlled, parallel, time-lagged, ascending, multi-centre, multiple-dose study to measure the magnitude and time course of the effect of FTY720 on FEV1 and other pulmonary function tests (FVC, FEF25-75%, and FEV1/FVC) in patients with moderate asthma
• To measure the magnitude and time course of the effect of FTY720 on FEV1 and other pulmonary function tests (FVC, FEF25-75%, and FEV1/FVC) in patients with moderate asthma. • To assess the safety an...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma AG
MAJ Il y a 5 ans
Study of safety and tolerability and preliminary efficacy of LNA043 in patients undergoing autologous chondrocyte implantation
• To assess the efficacy of a single LNA043 i.a. injection in regenerating hyaline cartilage tissue at the donor sites of patients undergoing autologous chondrocyte implantation (ACI) • To assess saf...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma AG
MAJ Il y a 5 ans
A multinational, multicenter, randomized, double-blind, double-dummy, stratified, active controlled parallel group study comparing the efficacy and safety of intravenous zoledronic acid, 5 mg once yearly, and oral risedronate, 5 mg daily, in the prevention and treatment of corticosteroid induced osteoporosis
to demonstrate that the percent change in lumbar spine BMD at Month 12 relative to baseline in male and female patients treated with one iv zoledronic acid 5 mg dose at randomization is not inferior ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma AG
MAJ Il y a 5 ans
Efficacy of secukinumab compared to adalimumab in patients with psoriatic arthritis
To demonstrate that the efficacy of secukinumab monotherapy (300 mg s.c.) at Week 52 is superior to adalimumab monotherapy (40 mg s.c.) based on the proportion of subjects achieving an American Colleg...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma AG
MAJ Il y a 5 ans
Study of safety and efficacy of PDR001 in combination with dabrafenib and trametinib in patients with a genetically distinct subtype of unresectable or metastatic melanoma, which is characterised by a mutation in the BRAF gene
Part 1: Safety run-in To determine the recommended regimen of PDR001 in combination with dabrafenib and trametinib for the randomized part (part 3) Part 2: Biomarker cohort To evaluate changes ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma AG
MAJ Il y a 5 ans
Efficacy, safety and pharmacokinetics of artemether-lumefantrine dispersible tablet in the treatment of malaria in infants < 5 kg
To evaluate the efficacy of a 3-day regimen of artemether-lumefantrine dispersible in infants <5 kg of BW with acute uncomplicated P. falciparum malaria using the polymerase chain reaction (PCR)-corre...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma AG
MAJ Il y a 5 ans
Study of safety, tolerability and preliminary efficacy of multiple intra-articular LNA043 injections in patients with articular cartilage lesions
• To assess the efficacy of multiple i.a. injections of LNA043 in regenerating the articular cartilage tissue • To assess safety and local tolerability of multiple i.a. injections of LNA043
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma AG
MAJ Il y a 5 ans
An extension study of safety of canakinumab in Japanese patients with periodic fever syndromes
The primary objective of this study is to evaluate safety and tolerability of ACZ885 in this extension study. This extension study offers the opportunity for patients who completed Epoch 4 of the prec...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
1
2
3
4
5
6
7
Suivant